Gonorrhea (Neisseria gonorrhoeae Infection) — Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Gonorrhea is a sexually transmitted bacterial infection caused by Neisseria gonorrhoeae, a Gram-negative, oxidase-positive, obligate human diplococcus. It is the second most common notifiable bacterial STI globally after chlamydia. Infection most commonly involves the mucosal epithelium of the urogenital tract (urethra, endocervix), but also infects the rectum, oropharynx, and conjunctiva, and can disseminate hematogenously to cause systemic disease (disseminated gonococcal infection, DGI). Untreated infection in women is a leading preventable cause of pelvic inflammatory disease (PID), tubal infertility, and ectopic pregnancy; in neonates it causes a sight-threatening ophthalmia neonatorum. N. gonorrhoeae is an obligate human pathogen with no other natural reservoir (PMID:35489793 — "Neisseria gonorrhoeae physiology and pathogenesis," comprehensive review, Adv Microb Physiol 2022).

Key identifiers: - MONDO: MONDO:0004277 (gonorrhea) - ICD-10-CM: A54 (Gonococcal infection), with subcodes A54.0 (lower genitourinary tract, no abscess), A54.1 (with periurethral/accessory gland abscess), A54.2 (pelviperitonitis and other genitourinary), A54.3 (eye), A54.4 (musculoskeletal), A54.5 (pharynx), A54.6 (anus/rectum), A54.8 (other), A54.9 (unspecified) - ICD-11 (MMS): 1A72 Gonococcal infection (with site-specific extension codes) - MeSH: D006069 (Gonorrhea); organism MeSH D009349 (Neisseria gonorrhoeae) - Orphanet: not a rare disease — no ORPHA code (common infectious STI, outside Orphanet's rare-disease scope) - NCBITaxon: NCBITaxon:485 (Neisseria gonorrhoeae)

Synonyms: "the clap," gonococcal infection, GC infection, gonococcal urethritis/cervicitis, gonococcemia (for disseminated disease).

Data provenance note: Most quantitative claims below derive from aggregated, disease-level public-health surveillance (CDC NNDSS/STI Surveillance reports, WHO global STI estimates) and case-series/cohort literature rather than individual EHR data, consistent with an infectious disease whose primary curation sources are population surveillance and clinical microbiology literature rather than genetic registries.

2. Etiology

Disease Causal Factor

The sole causal agent is infection with Neisseria gonorrhoeae. This is a purely infectious etiology — there is no genetic Mendelian basis for the disease itself (as distinct from host susceptibility modifiers, below). Transmission is via direct mucosal contact — genital, anorectal, or oropharyngeal sexual contact, or perinatal (mother-to-child) transmission during vaginal delivery.

Risk Factors

Environmental / behavioral risk factors (PMID:35489793; CDC STI Surveillance 2024): - Multiple or new sexual partners; unprotected (condomless) intercourse - Age 15–24 years (highest incidence band in most surveillance systems) - Men who have sex with men (MSM) — disproportionately high rectal/pharyngeal incidence - Prior gonorrhea or other STI (marker of ongoing exposure risk) - Sex work; high local community prevalence ("core group" transmission dynamics) - Illicit drug use, incarceration history, and inconsistent healthcare access (social determinants correlated with surveillance-reported incidence, CDC 2024 STI Surveillance Report, https://www.cdc.gov/sti-statistics/annual/index.html) - Co-infection with other STIs (chlamydia, syphilis, trichomoniasis) — shared risk-factor and mucosal-vulnerability profile

Genetic / host susceptibility risk factors: - Terminal complement pathway deficiencies (C5, C6, C7, C8, C9 and Factor I/Factor H of the alternative pathway) markedly predispose to disseminated and recurrent neisserial infection (both meningococcal and gonococcal), because the membrane attack complex (MAC) is the principal bactericidal mechanism against Neisseria in blood. A 2026 case report describes disseminated gonococcal infection due to a homozygous nonsense mutation in CFI (Factor I; p.Arg474) causing complete Factor I deficiency (PMID:41607490, PMC12829745). A separate case describes DGI in a man with compound-heterozygous C7 deficiency (PMC8021336). "Deficiencies of components of the alternative and terminal complement pathways have long been implicated in increasing the risk for neisserial infections." - Acquired complement deficiency (e.g., hypocomplementemic urticarial vasculitis, systemic lupus erythematosus with autoantibody-mediated complement consumption) has also been linked to extreme gonococcal susceptibility. - CEACAM receptor polymorphism/expression variability* on genital epithelium modulates strain-specific Opa-mediated adhesion/invasion susceptibility, though this is a variable host receptor-expression trait rather than a Mendelian risk allele (see Mechanism, §6).

Suggested ontology terms: HP:0005361 (Recurrent bacterial infections context — as HPO does not carry a "gonorrhea susceptibility" term per se, complement deficiency phenotypes are better captured via the causal gene); HGNC gene symbols for host modifier genes: CFI (hgnc:5394), C7 (hgnc:1346), C6 (hgnc:1339), C8A/C8B/C8G, C9 (hgnc:1358), CFH (hgnc:4883).

Protective Factors

• Consistent condom use (mechanical barrier to mucosal contact)
• Meningococcal serogroup B outer-membrane-vesicle (OMV) vaccines (4CMenB/Bexsero, and the earlier MeNZB) show cross-protective effectiveness against gonorrhea due to genomic/antigenic homology between N. meningitidis and N. gonorrhoeae — a landmark finding in STI vaccinology (see §13, Prevention).
• No known protective human genetic alleles specific to gonococcal infection have been robustly established (unlike, e.g., sickle trait for malaria); complement sufficiency is simply the normal protective state, not a "protective variant."

Gene–Environment Interactions

The clearest gene–environment interaction is that an otherwise ordinary sexual exposure produces disseminated rather than localized infection specifically in hosts with terminal-complement-pathway lesions — i.e., the same environmental exposure (mucosal inoculation) yields a qualitatively different, more severe phenotype conditioned on host complement genotype (PMID:41607490; PMC8021336). This is the dominant, well-documented gene×environment axis for this disease; there is no evidence for polygenic susceptibility loci from GWAS at this time.

3. Phenotypes

Gonorrhea phenotypes are strongly site-dependent and frequently asymptomatic, which is itself an important epidemiological/clinical phenotype (~50% of women and up to 10% of men with urogenital infection are asymptomatic; pharyngeal and rectal infections are asymptomatic in the majority of cases; PMID:35489793 and CDC clinical guidance).

A. Uncomplicated urogenital infection

B. Extragenital/site-specific infection

C. Ascending / complicated disease

D. Disseminated gonococcal infection (DGI) — hematogenous spread (~0.5–3% of untreated infections)

Two classical clinical patterns (PMC11368578, PMC12701954): 1. Triad form: fever, dermatitis (pustular/vesiculopustular skin lesions on an erythematous base, typically acral), migratory polyarthralgia, and tenosynovitis (asymmetric, affecting wrists/fingers/knees/ankles) 2. Purulent monoarticular/oligoarticular septic arthritis — abrupt-onset asymmetric joint pain/swelling, often afebrile - Rare but severe: endocarditis, meningitis, osteomyelitis (PMC9602952 — gonococcal meningitis) - Strains from disseminated sites are disproportionately of the transparent (Opa-low) phenotype (90% in classic series), reflecting serum-resistance/immune-evasion phenotype selection for bloodstream survival

Suggested HP terms: HP:0001945 (Fever), HP:0100546 (Arthralgia), HP:0001369 (Arthritis), HP:0001386 (Joint swelling), HP:0100678 (Skin nodule)/pustular rash, HP:0100033 (Osteomyelitis), HP:0001297 (Stroke) N/A, HP:0001298 (Encephalopathy)/meningitis-related terms, HP:0030842 (Infective endocarditis).

E. Neonatal

Quality of life impact

Asymptomatic and untreated infection drives ongoing transmission; symptomatic disease causes acute discomfort (dysuria, discharge, pelvic pain) and — critically — the downstream PID/infertility/ectopic pregnancy sequelae carry major reproductive-health and psychosocial quality-of-life burden in women of reproductive age. DGI-associated arthritis causes acute functional disability. No disease-specific validated QoL instrument was identified; general STI-related psychosocial burden is documented in the PID and infertility literature (PMID:12346974 — immunopathogenesis of PID and infertility).

4. Genetic/Molecular Information

Gonorrhea is not a human Mendelian disease — there is no human causal gene. The relevant "genetics" for this KB entry falls into two categories:

A. Host modifier/susceptibility genes (see §2)

• CFI (Complement Factor I, hgnc:5394) — homozygous loss-of-function → complete Factor I deficiency → extreme susceptibility to disseminated/recurrent neisserial infection (PMID:41607490)
• C7 (hgnc:1346), C6, C8A/C8B/C8G, C9 — terminal complement component deficiencies → impaired membrane attack complex formation → recurrent/disseminated neisserial disease (PMC8021336)
• CFH — alternative pathway regulator; acquired/functional deficiency states similarly predispose

Relationship type for genetic annotation: MODIFIER/SUSCEPTIBILITY (not CAUSAL), since these genes govern severity/dissemination of an exogenous infection rather than causing the disease de novo.

B. Pathogen (bacterial) genetics — antimicrobial resistance determinants

These are not human genes but are central to modern gonorrhea molecular epidemiology and directly determine treatment mechanism/failure:

(PMC5628311 — comprehensive review "Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat"; PMC9045316 — reliability of genetic markers for predicting ceftriaxone resistance globally.) The WHO in November 2021 flagged emerging ceftriaxone resistance/treatment-failure strains as a global AMR priority.

C. Epigenetic / chromosomal

No disease-relevant human epigenetic or chromosomal-abnormality literature applies (not a genetic disease). N. gonorrhoeae itself undergoes extensive phase and antigenic variation (Opa gene slipped-strand mispairing, pilin antigenic variation via recombination with silent pilS loci) — a bacterial "epigenetic-like" mechanism of immune evasion, distinct from human epigenetics (PMID:35489793).

Suggested ontology terms: GO:0046677 (response to antibiotic), GO:0015562 (efflux transmembrane transporter activity) for MtrCDE; CHEBI terms for antibiotics (§12).

5. Environmental Information

• Infectious agent (primary etiology): Neisseria gonorrhoeae, NCBITaxon:485; Gram-negative diplococcus, family Neisseriaceae. Obligate human pathogen, no environmental or animal reservoir; transmitted exclusively via direct mucosal contact (sexual or perinatal).
• Behavioral/lifestyle factors: unprotected sexual contact, multiple partners, sex work, substance use in sexual contexts (see §2 Risk Factors) — CDC/WHO surveillance sources.
• No chemical/toxin/occupational environmental etiology applies; this is purely a sexually/perinatally transmitted bacterial infection.
• Co-circulating pathogen environment: commensal Neisseria species (N. lactamica, N. cinerea, N. meningitidis, N. polysaccharea) in the oropharynx serve as a genetic reservoir for horizontal transfer of resistance determinants (mosaic mtr, penA alleles) into N. gonorrhoeae — the oropharynx is thus an important "environmental" site for AMR emergence (PMC6134098).

Suggested ontology terms: ECTO term for "exposure to sexually transmitted infectious agent" (no highly specific ECTO term for STI contact currently cataloged — would need OAK lookup); NCBITaxon:485 for the organism.

6. Mechanism / Pathophysiology

Causal chain overview

Mucosal exposure → colonization/adherence → epithelial invasion & transcytosis → local inflammatory response (neutrophil influx) → tissue damage / discharge → (if untreated) ascending/hematogenous spread → PID/DGI sequelae.

6.1 Colonization and adherence (initiating step)

• Type IV pili (Tfp) mediate initial long-range attachment to mucosal epithelium and microcolony formation; pilin (PilE) undergoes high-frequency antigenic variation via recombination with silent pilS loci, and pilus retraction generates twitching motility (PMID:35489793).
• Opacity-associated (Opa) proteins — up to 11 phase-variable paralogs — mediate tighter adhesion and, when engaged with host CEACAM family receptors (CEACAM1, CEACAM3, CEA/CEACAM5, CEACAM6), promote receptor-mediated invasion/transcytosis of epithelial cells (PMID:21204865 — Opa proteins and CEACAMs review, FEMS Microbiol Rev). Differential CEACAM expression along the female reproductive tract determines the outcome (colonization vs. invasion vs. clearance) of infection at different anatomic sites (journals.asm.org/iai.00092-18). Notably, CEACAM engagement is not strictly required — Opa+ gonococci can adhere to/invade genital epithelial cells via heparan sulfate proteoglycans (HSPG) independent of CEACAM (PMID:11580753).
• Porin (PorB) also contributes to adherence and, upon translocation into host mitochondrial and plasma membranes, modulates host-cell apoptosis and calcium flux.

6.2 Immune evasion (central pathogenic strategy)

• Lipooligosaccharide (LOS) sialylation, using host-derived CMP-NANA, masks LOS and blocks classical/alternative complement pathway activation and opsonophagocytic killing — a major serum-resistance mechanism.
• Anti-phagocytic mechanisms allow intracellular survival within neutrophils via direct interference with the oxidative burst (NADPH oxidase assembly) and delayed phagolysosome maturation, permitting the organism to persist within — rather than be cleared by — the very cells recruited to fight it (PMC4154863 — "Global Analysis of Neutrophil Responses to Neisseria gonorrhoeae Reveals a Self-Propagating Inflammatory Program").
• Antigenic and phase variation (Opa, pilin, LOS) generates within-host antigenic diversity that impedes adaptive immune clearance and explains the striking absence of protective natural immunity/reinfection resistance.
• Macrophage polarization to an M2 (anti-inflammatory/less microbicidal) phenotype by gonococcal infection has been demonstrated as an additional subversion strategy (PMC4488386).

6.3 Inflammatory tissue damage (downstream of colonization)

• Rather than direct cytotoxicity, gonococcal pathology is substantially immunopathological: sustained neutrophil influx that fails to clear the organism instead releases antimicrobial products (reactive oxygen species, proteases, defensins) that damage host mucosa — producing the purulent discharge that is the clinical hallmark of infection (PMID:35489793, PMC4154863).
• In the fallopian tube, IL-17C has been identified as a driver of damaging inflammation during ex vivo N. gonorrhoeae infection of human Fallopian tube explants, contributing to ciliated-cell sloughing, epithelial exfoliation, tubal scarring, and eventual occlusion (Nature Communications 2024, DOI:10.1038/s41467-024-48141-3; PMC11069574).
• Progressive fallopian tube damage → PID → chronic pelvic pain, tubal-factor infertility, ectopic pregnancy (immunopathogenesis reviewed PMID:12346974).

6.4 Dissemination (hematogenous spread → DGI)

• Strains with the transparent (Opa-low) phenotype and LOS sialylation/serum-resistance are preferentially recovered from blood/synovial fluid in DGI, reflecting selection for bloodstream survival over epithelial adherence.
• Host terminal complement pathway deficiency removes the primary bactericidal barrier to bacteremia, explaining recurrent/disseminated presentations in affected individuals (§2, §4).
• Disseminated organisms seed skin (pustular dermatitis), joints/tendon sheaths (septic arthritis/tenosynovitis), and rarely heart valves, meninges, or bone.

Cell types and processes involved

• Cell types: genital/cervical/urethral/rectal/pharyngeal/conjunctival columnar and stratified epithelial cells (site-specific tropism), neutrophils (CL:0000775), macrophages (CL:0000235), fallopian tube ciliated epithelial cells (CL:1000272 or similar), synoviocytes (DGI arthritis).
• Suggested GO biological process terms: GO:0007155 (cell adhesion), GO:0044409 (entry into host), GO:0052255 (modulation by symbiont of host innate immune response), GO:0006956 (complement activation) — as a target of evasion, GO:0002532 (production of molecular mediator involved in inflammatory response), GO:0043312 (neutrophil degranulation).
• Suggested UBERON terms: UBERON:0000056 (ureter — n/a), UBERON:0000057 (urethra), UBERON:0000995 (uterine cervix), UBERON:0003889 (fallopian tube), UBERON:0004908 (oropharynx), UBERON:0001358 (cerebrospinal fluid — meningitis), UBERON:0002370 (thymus — n/a); UBERON:0000966 (retina — n/a) — more precisely UBERON:0001759 (conjunctiva) for ophthalmia neonatorum, UBERON:0001474 (bone element) for osteomyelitis, UBERON:0000982 (synovial fluid)/UBERON:0001466 (synovial joint) for DGI arthritis.
• Suggested CHEBI terms (host/pathogen molecules): CHEBI:24433 (lipooligosaccharide — approximate; LOS is not a single well-defined CHEBI entity but relevant chemical class), CHEBI for sialic acid (CHEBI:26667, N-acetylneuraminic acid).

7. Anatomical Structures Affected

Organ/system level: - Primary: male and female lower genitourinary tract (urethra, endocervix, Skene's/Bartholin's glands), rectum, pharynx, conjunctiva - Secondary (ascending/complications): fallopian tubes, ovaries, peritoneum (pelviperitonitis), epididymis, prostate, liver capsule (Fitz-Hugh-Curtis) - Disseminated: skin, synovial joints/tendon sheaths, heart valves (rare endocarditis), meninges (rare meningitis), bone (rare osteomyelitis) - Body systems: reproductive system, integumentary system, musculoskeletal system, ocular system, and rarely cardiovascular and central nervous systems

Tissue/cell level: columnar/transitional epithelium (urethra, endocervix, rectum), stratified squamous epithelium (vagina — relatively resistant to colonization compared to columnar epithelium sites), ciliated fallopian tube epithelium, synovium, conjunctival epithelium.

Subcellular level: phagosome/phagolysosome (site of intracellular neutrophil survival), plasma membrane and mitochondrial membrane (PorB translocation), outer membrane (LOS/Opa/pilin expression).

Suggested UBERON terms: UBERON:0000057 (urethra), UBERON:0000995 (uterine cervix), UBERON:0003889 (fallopian tube/oviduct), UBERON:0001350 (coelomic cavity/peritoneum — approx UBERON:0002358 for peritoneal cavity), UBERON:0004908 (oropharynx), UBERON:0001759 (conjunctiva), UBERON:0001466 (synovial joint), UBERON:0002107 (liver — Fitz-Hugh-Curtis), UBERON:0001474 (bone element).

8. Temporal Development

Onset: - Incubation period: typically 2–7 days post-exposure for symptomatic urethral infection in men (classic range); cervical/rectal/pharyngeal infection incubation is less well defined and often clinically silent. - Onset pattern: acute for symptomatic urogenital disease; frequently asymptomatic/subclinical at cervical, rectal, and pharyngeal sites, which is itself the key epidemiologic driver of ongoing transmission. - Neonatal ophthalmia neonatorum: onset within the first 5 days of life, reflecting intrapartum exposure timing.

Progression: - Untreated urogenital infection may spontaneously clear over weeks-to-months in a fraction of cases, but a substantial proportion progresses to ascending infection. - PID typically develops days to weeks after untreated cervical infection; roughly 10–15% of women with untreated gonorrhea (or chlamydia) develop PID. - DGI develops in an estimated 0.5–3% of untreated gonococcal infections, usually within days to a few weeks of the primary mucosal infection, and can present acutely (arthritis-dermatitis syndrome, days) or with the purulent-arthritis pattern. - Disease course is not chronic/progressive in the classic autoimmune-disease sense; it is an acute-to-subacute bacterial infection whose "chronicity" manifests as (a) persistent untreated colonization enabling transmission and (b) fibrotic/scarring sequelae (tubal occlusion, adhesions) that are permanent once established, even after microbiological cure.

Patterns: - No spontaneous remission-relapse pattern in the classic sense; recurrence is virtually always reinfection from an untreated/new partner rather than true relapse, given lack of durable protective immunity and high antigenic variability. - Critical intervention window: early antibiotic treatment before ascending spread prevents essentially all PID/tubal-damage sequelae — this is the central rationale for STI screening programs.

9. Inheritance and Population

Not a genetically inherited disease — inheritance-pattern fields (AD/AR/X-linked, penetrance, expressivity, anticipation, founder effects, consanguinity, carrier frequency) are not applicable to gonorrhea itself. (They would be applicable only to the rare host complement-deficiency modifier genes noted in §2/§4, which follow autosomal recessive inheritance for the classic terminal-complement-component deficiencies.)

Epidemiology: - Global incidence (WHO, 2020 estimate): approximately 82.4 million new infections among adults aged 15–49 worldwide in 2020 (WHO fact sheet, https://www.who.int/news-room/fact-sheets/detail/gonorrhoea-(neisseria-gonorrhoeae-infection); WHO Nov 2021 AMR surveillance report). It is the second most common bacterial STI after chlamydia. - United States (CDC 2024 provisional surveillance): Gonorrhea cases declined for a third consecutive year, down ~10% from 2023; combined chlamydia/gonorrhea/syphilis cases fell 9% from 2023. However, total 2024 U.S. STIs (all types) still exceeded 2.2 million reported cases, and overall STI burden remains 13% higher than a decade prior (CDC 2024 STI Surveillance report, https://www.cdc.gov/sti-statistics/annual/index.html; https://www.hiv.gov/blog/cdc-releases-2024-national-sti-data). - Possible contributor to the recent U.S. decline: expanded meningococcal B vaccine use in college-age/high-risk adults, given documented cross-protection against gonorrhea (see §13). - Disseminated gonococcal infection (DGI) surveillance in the U.S., 2020–2022 (PMC9751791, "Mind the Clap").

Population demographics: - Age distribution: highest incidence in 15–24-year-olds, reflecting sexual-activity patterns and behavioral/biological (cervical ectopy) susceptibility in young women. - Sex/behavioral group distribution: disproportionately high burden among men who have sex with men (MSM), particularly for rectal and pharyngeal infection; also elevated among sex workers, transgender women, and adolescents/young adults in high-burden settings (WHO fact sheet). - Geographic distribution: globally endemic, with the highest burden in the WHO African and Western Pacific regions per global estimates; substantial regional variation in antimicrobial-resistance prevalence — e.g., high tetracycline resistance prevalence across 22 European countries in 2024 surveillance (PMC12811707). - Racial/ethnic and state-level U.S. breakdowns for 2024 were not yet released by CDC at time of the 2024 provisional report due to ongoing surveillance-system updates (Healthbeat, https://www.healthbeat.org/2025/10/07/sti-chlamydia-gonorrhea-syphilis-cdc-data/).

Suggested ontology term: NCBITaxon:9606 (Homo sapiens, sole natural host).

10. Diagnostics

Clinical/laboratory tests: - Nucleic acid amplification testing (NAAT) is the current diagnostic standard of care — highly sensitive and specific for genital specimens (urine, urethral/endocervical/vaginal swabs), and validated for extragenital (rectal, oropharyngeal) specimens where it substantially outperforms culture (PMID:20335410; PMID:18520976; PMC1871692 "Nucleic Acid Amplification Testing for Neisseria gonorrhoeae: An Ongoing Challenge"; PMC8769746 multicenter NAAT comparison for rectal/oropharyngeal specimens). Commercial platforms include Gen-Probe APTIMA COMBO 2/APTIMA GC, Roche COBAS Amplicor/4800 CT/NG, BD ProbeTec, Abbott RealTime CT/NG (PMC3187337). - Important caveat: false-positive NAAT results can occur due to horizontal genetic exchange between N. gonorrhoeae and commensal Neisseria species sharing amplified target sequences — an important diagnostic-interpretation caveat, especially at pharyngeal sites. - Culture (Thayer-Martin or modified selective media) remains essential for antimicrobial susceptibility testing and outbreak/AMR surveillance, despite lower sensitivity than NAAT, particularly for extragenital sites. - Gram stain of urethral discharge in symptomatic men (intracellular Gram-negative diplococci within neutrophils) remains a rapid point-of-care diagnostic with high sensitivity/specificity in that specific clinical context, though far less reliable for cervical, rectal, or pharyngeal specimens. - Molecular AMR prediction: genotypic assays targeting gyrA (ciprofloxacin susceptibility screening via detection of wild-type S91), and increasingly whole-genome-sequencing-based prediction of penA/mtrR/23S rRNA resistance markers, though reliability of genotype-based ceftriaxone-resistance prediction remains imperfect globally (PMC9045316).

Genetic testing: Not applicable in the human-genetics sense (no causal human gene); pathogen molecular typing (NG-MAST, NG-STAR, whole-genome sequencing) is used for surveillance and AMR-marker detection rather than "genetic testing" of the patient.

Omics-based diagnostics: Whole-genome sequencing of clinical isolates is increasingly used for AMR surveillance and outbreak/transmission-cluster tracking (PMC8442004, "Recent advances in understanding and combatting Neisseria gonorrhoeae: a genomic perspective") — this is pathogen genomics, not host omics.

Clinical criteria / differential diagnosis: Urethritis/cervicitis differential includes Chlamydia trachomatis (frequent co-infection — CDC recommends empiric doxycycline co-treatment when chlamydia is not excluded), Mycoplasma genitalium, Trichomonas vaginalis, and non-infectious urethritis/cervicitis. DGI arthritis-dermatitis syndrome differential includes reactive arthritis, viral exanthem-associated arthritis, and other causes of septic arthritis.

Screening: CDC/USPSTF recommend annual gonorrhea (and chlamydia) screening for sexually active women <25 years and older women with risk factors, and for MSM at exposed anatomic sites (urogenital, rectal, pharyngeal) at least annually (more frequently for high-risk individuals). Universal ocular prophylaxis at birth (erythromycin ointment historically; topical agents per current guidance) remains recommended in the U.S. for prevention of ophthalmia neonatorum (NBK537599 — USPSTF reaffirmation evidence review).

Suggested LOINC/ontology: LOINC panels exist for N. gonorrhoeae NAAT (e.g., LOINC:43304-5 and site-specific variants); SNOMED CT for clinical/pathology findings.

11. Outcome/Prognosis

• Mortality: Direct mortality from uncomplicated gonorrhea is essentially negligible with treatment; mortality is confined to rare severe DGI complications (endocarditis, meningitis) and to indirect mortality via ectopic pregnancy, which remains a life-threatening PID sequela.
• Morbidity: The dominant morbidity burden is reproductive: an estimated 10–15% of women with untreated gonorrhea/chlamydia develop PID; PID prevalence among reproductive-age U.S. women is estimated at 4.1%, with N. gonorrhoeae implicated in roughly a third of cases (Illinois DPH; PMID:23007248). PID sequelae include chronic pelvic pain, tubal-factor infertility, and ectopic pregnancy.
• Recovery potential: With prompt, effective antibiotic treatment, uncomplicated mucosal infection resolves completely with no long-term sequelae. Once tubal scarring/occlusion has occurred, however, infertility and elevated ectopic-pregnancy risk are not reversible by subsequent antibiotic treatment — underscoring the importance of early detection given the high asymptomatic-carriage rate.
• DGI outcomes: With appropriate IV/IM antibiotic therapy, DGI arthritis-dermatitis syndrome and septic arthritis generally resolve without permanent joint damage if treated promptly; delayed treatment risks joint destruction from septic arthritis and, rarely, endocarditis/meningitis-related mortality/morbidity.
• Prognostic factors: delay to treatment (strongest driver of PID/tubal-damage risk), host complement status (drives DGI risk), and infecting strain's antimicrobial susceptibility profile (treatment-failure risk with resistant strains is an emerging and consequential prognostic factor per WHO AMR surveillance, 2021).
• HIV interaction: gonococcal (especially rectal) co-infection is independently associated with substantially increased HIV acquisition and transmission risk — a 2–5-fold increase in susceptibility attributed to mucosal epithelial damage and increased local HIV target-cell recruitment/viral shedding (PMC5779692 — N. gonorrhoeae co-infection exacerbates vaginal HIV shedding in a humanized mouse model; academic.oup.com/ofid — repeated rectal gonorrhea independently associated with incident HIV infection risk in MSM). This materially worsens long-term prognosis in co-infected populations by amplifying HIV epidemic spread.

12. Treatment

Current first-line pharmacotherapy (CDC 2021 STI Treatment Guidelines, updated 2020 recommendations; PMID:35416971, academic.oup.com/cid supplement): - Ceftriaxone 500 mg IM single dose (uncomplicated infection of any anatomic site — genital, rectal, pharyngeal) — increased to 1 g IM for patients weighing ≥150 kg (300 lb). - This replaced the prior dual-therapy regimen of ceftriaxone 250 mg IM + azithromycin 1 g PO, reflecting rising azithromycin resistance concerns and evidence that single-agent ceftriaxone is highly effective, reducing selective pressure for macrolide resistance. - Co-treatment for chlamydia: if chlamydial co-infection has not been excluded, add doxycycline 100 mg PO BID × 7 days. - Cephalosporin-allergic patients: limited alternatives exist; no recommended alternative regimen for pharyngeal infection specifically, reflecting the therapeutic difficulty of that site; oral cefixime 800 mg single dose may be used for expedited partner therapy (EPT) when injectable ceftriaxone is not feasible, though it is not preferred given lower efficacy at some anatomic sites and resistance concerns. - DGI (disseminated disease): requires initial parenteral ceftriaxone (typically 1 g IV/IM daily) for a longer course, often transitioning to oral therapy after clinical improvement, per site-specific severity (arthritis, meningitis, endocarditis regimens differ in duration/dose). - Ophthalmia neonatorum: ceftriaxone (single IM/IV dose, weight-based) plus saline eye irrigation; prevention via universal neonatal ocular prophylaxis remains standard of care.

Pharmacogenomics: No clinically significant host pharmacogenomic determinants of gonorrhea drug response have been established (unlike, e.g., HLA-linked hypersensitivity syndromes for other drugs); the dominant "resistance genomics" concern is pathogen genotype (§4/§9), not host genotype.

Advanced/experimental therapeutics: No gene therapy, cell therapy, RNA-based therapy, or targeted/immunotherapy applies to this bacterial infection; management is exclusively antimicrobial.

Surgical/interventional: Reserved for complications — e.g., drainage of tubo-ovarian abscess, arthrocentesis/surgical debridement for severe septic arthritis, laparoscopy for Fitz-Hugh-Curtis adhesion lysis/diagnosis.

Supportive care: symptomatic management of pain/discharge; partner notification and treatment (expedited partner therapy, EPT) is a core component of clinical management to prevent reinfection and interrupt transmission chains.

Treatment outcomes / resistance concerns: The central emerging treatment-outcome issue is antimicrobial resistance, with documented multidrug-resistant and ceftriaxone-resistant strains (mosaic penA alleles) reported globally, including in France (2022, PMC9808317) and elsewhere, prompting WHO to designate gonococcal AMR a global health priority (WHO, Nov 2021) and driving intensified interest in non-antibiotic prevention strategies (vaccines, see §13).

Suggested NCIT terms: - NCIT:C15986 (Pharmacotherapy) — generic action for the antibiotic regimens - NCIT:C15632 (Chemotherapy) — not applicable here (antibacterial, not chemo) - Therapeutic agents (CHEBI): ceftriaxone (CHEBI:3508), azithromycin (CHEBI:2955), doxycycline (CHEBI:50845), cefixime (CHEBI:475130), ciprofloxacin (CHEBI:100241) — verify exact CHEBI IDs via OAK lookup before curation. - NCIT:C15329 (Surgical Procedure) for abscess drainage/laparoscopy in complicated PID.

13. Prevention

Primary prevention: - Barrier contraception (consistent, correct condom use) remains the principal behavioral primary-prevention measure. - Behavioral risk-reduction counseling and partner-reduction strategies (CDC/WHO public health guidance). - Vaccination (major recent development): Meningococcal serogroup B outer-membrane-vesicle (OMV) vaccines — 4CMenB (Bexsero) and the earlier New Zealand MeNZB — demonstrate significant cross-protective effectiveness against gonorrhea, attributed to antigenic homology between N. meningitidis and N. gonorrhoeae OMV components: - 4CMenB induces cross-species protection against N. gonorrhoeae in preclinical models (PMC7748408/PMID:32218555, npj Vaccines). - A matched cohort study in Southern California found real-world protective effectiveness (PMID:35642527). - Multiple 2025 systematic reviews/meta-analyses confirm statistically significant reductions in gonorrhea incidence among OMV-MenB vaccine recipients versus unvaccinated or non-OMV-vaccinated comparators, with effectiveness estimates in the range of 23–46%, and one case-control estimate (using chlamydia as a negative control) of ~31% (PMID:40334533; academic.oup.com/jid/article/231/1/61; PMID:38986746). - Policy uptake: in August 2025, the UK Health Security Agency approved 4CMenB use specifically to prevent gonorrhea in high-risk populations, including individuals with repeat infections and MSM — the first national policy explicitly using a meningococcal vaccine for gonorrhea prevention. - Purpose-built gonococcal vaccines are in active development: GSK's investigational N. gonorrhoeae GMMA (Generalized Modules for Membrane Antigens) vaccine is in a Phase 1/2 clinical trial (NCT05630859); preclinical native-OMV candidate vaccines engineered from gonococcal strains (with lpxL1/rmp deletions to reduce reactogenicity) show promise compared to 4CMenB in animal models (npj Vaccines 2026, PMID:42259835). WHO identified gonorrhea vaccine development as a global priority in 2024, driven by rising antimicrobial resistance. - Caveat: breakthrough rectal N. gonorrhoeae infections after meningococcal B vaccination have been reported, underscoring that current cross-protection is partial, not sterilizing (academic.oup.com/ofid/article/11/11/ofae562).

Secondary prevention (screening/early detection): - Routine annual NAAT-based screening of sexually active women <25 and higher-risk older women, and of MSM at all exposed anatomic sites (§10). - Universal neonatal ocular prophylaxis at birth remains a longstanding, evidence-supported secondary/primary prevention measure against ophthalmia neonatorum (USPSTF reaffirmation, NBK537599).

Tertiary prevention: Prompt treatment of diagnosed infection and of PID specifically to minimize progression to tubal damage/infertility/ectopic pregnancy; partner treatment (EPT) to prevent reinfection cycles.

Public health interventions: Partner notification/contact tracing programs, expedited partner therapy (EPT) policies, community-based STI testing outreach in high-prevalence "core group" populations, and enhanced AMR surveillance (WHO Gonococcal Antimicrobial Surveillance Programme, GASP) to guide empiric treatment recommendations as resistance patterns shift regionally.

Prophylaxis: No pre-exposure chemoprophylaxis is currently recommended for gonorrhea specifically (in contrast to doxycycline post-exposure prophylaxis, "doxy-PEP," which is increasingly used for chlamydia/syphilis prevention in high-risk MSM populations but has shown limited/inconsistent efficacy specifically against gonorrhea due to existing tetracycline-class resistance).

14. Other Species / Natural Disease

N. gonorrhoeae is a strict human-obligate pathogen with no natural non-human reservoir or naturally occurring disease in animals. This is a defining biological feature of the organism (unlike, e.g., zoonotic pathogens). - Taxonomy: NCBITaxon:485 (Neisseria gonorrhoeae); genus Neisseria (NCBITaxon:482) includes related pathogenic species N. meningitidis (NCBITaxon:487) and commensal species (N. lactamica, NCBITaxon:489; N. cinerea; N. polysaccharea) that participate in horizontal AMR gene transfer (§4, §5). - No breed-specific (VBO) relevance — not an animal disease. - No natural veterinary disease is recognized; N. gonorrhoeae does not naturally infect animals, so there is no OMIA entry or veterinary comparative-pathology literature analogous to a zoonosis. - Zoonotic potential: none — transmission is exclusively human-to-human (sexual or perinatal).

15. Model Organisms

Because N. gonorrhoeae is a strict human pathogen, animal models require special adaptation and none fully recapitulates human disease; each has defined utility and limitations.

Female mouse model (the dominant experimental system): - Wild-type mice are naturally resistant to gonococcal genital colonization (PMID:2506350, "Resistance of mice to genital infection with Neisseria gonorrhoeae"). - Estradiol-treated female mice serve as surrogate hosts: exogenous 17β-estradiol treatment (which thins the vaginal epithelium toward a more human-cervix-like columnar-favorable state and suppresses normal murine flora) permits reproducible lower-genital-tract colonization that recapitulates many features of human infection, including innate immune responses and gonococcal genetic requirements for in vivo fitness (PMID:21747807, "Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections," Front Microbiol 2011; developed principally by the Jerse laboratory, Uniformed Services University). - This model has been used extensively for antimicrobial efficacy testing (e.g., auranofin efficacy against gonococcal genital infection, PMC9022871) and for vaccine preclinical efficacy testing (e.g., OMV candidate vaccine vs. 4CMenB comparison, npj Vaccines 2026). - Limitations: requires exogenous hormone manipulation (not physiologic estrus), does not reproduce upper-tract ascension/PID or DGI pathology, and murine complement/CEACAM/receptor biology differs from human, limiting some immune-evasion and adhesion-mechanism studies to in vitro human-cell systems. - Review: PMID:28886683, "Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development," Annu Rev Microbiol 2017.

Other model systems: - Human ex vivo Fallopian tube organ culture — used to directly study PID-relevant tubal damage mechanisms (e.g., the IL-17C inflammatory-damage studies, PMC11069574/PMC (bioRxiv) 2022) — arguably the most human-fidelity model for upper-tract pathology, since no rodent naturally recapitulates fallopian tube disease. - Human cell-line/primary epithelial cell culture (cervical, urethral epithelial lines; polarized epithelial monolayers) — used extensively for adhesion/invasion/Opa-CEACAM mechanism studies (§6). - Humanized (CD34+ engrafted) mouse models — used specifically to study N. gonorrhoeae–HIV co-infection interactions in a system with human immune cells, demonstrating exacerbated vaginal HIV shedding during gonococcal co-infection (PMC5779692). - Zebrafish, Drosophila, C. elegans, yeast: no established gonorrhea disease models identified in the literature searched — N. gonorrhoeae research relies predominantly on the estradiol mouse model and human ex vivo/cell-culture systems given the organism's human-restricted tropism.

Suggested model-organism ontology terms: NCBITaxon:10090 (Mus musculus), model type "induced infection model" (hormone-primed genital colonization); MGI resources for background mouse strain records; Cellosaurus IDs for relevant human epithelial cell lines used in adhesion/invasion assays (e.g., ME-180, HEC-1-B cervical lines — verify via literature before citing specific Cellosaurus accessions).

Summary of Key Ontology Term Suggestions for KB Curation

Sources

• Neisseria gonorrhoeae physiology and pathogenesis (PMID:35489793)
• Mechanisms of host manipulation by Neisseria gonorrhoeae
• Neisseria gonorrhoeae Modulates Immunity by Polarizing Human Macrophages to a M2 Profile
• Global Analysis of Neutrophil Responses to Neisseria gonorrhoeae
• CDC STI Statistics 2024 (Provisional)
• CDC Releases 2024 National STI Data (HIV.gov)
• Are STDs truly declining? Dissecting the 2024 CDC report (Healthbeat)
• Mind the Clap: Reported Disseminated Gonococcal Infections, 2020-2022
• Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms (PMC5628311)
• Reliability of Genetic Alterations in Predicting Ceftriaxone Resistance (PMC9045316)
• Ceftriaxone-resistant, multidrug-resistant N. gonorrhoeae, mosaic penA-237.001, France 2022
• Mosaic mtr efflux gene sequences and azithromycin resistance (PMC6134098)
• Azithromycin Resistance through Interspecific Acquisition (PMC6083905)
• Gonococcal meningitis: unusual presentation of DGI
• Disseminated gonococcal infection (DGI) and gonococcal arthritis - PMID:6112797
• Disseminated gonococcal infection: prospective analysis of 49 patients - PMID:6415361
• Disseminated Gonococcal Infection Presenting as Isolated Septic Arthritis
• Gonococcal Tenosynovitis With Abscess Formation
• Disseminated gonococcal infection secondary to complement factor I deficiency (PMID:41607490)
• DGI in a man with complement 7 deficiency
• Extreme gonococcal susceptibility with acquired complement deficiency (HUV/SLE)
• Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum - USPSTF Evidence Update
• Ophthalmia Neonatorum - StatPearls
• Pelvic Inflammatory Disease (PID) from Chlamydia vs. Gonorrhea (PMID:23007248)
• Immunopathogenesis of PID and infertility (PMID:12346974)
• IL-17C driver of damaging inflammation in Fallopian tube infection (PMC11069574)
• Fitz-Hugh-Curtis Syndrome - StatPearls
• Gonorrhoic perihepatitis. Fitz-Hugh-Curtis syndrome (PMID:6769152)
• Evaluating cross-protection: Meningococcal vaccines and gonorrhoea prevention meta-analysis (PMID:40334533)
• 4CMenB induces cross-species protection against Neisseria gonorrhoeae (PMC7748408)
• Prevention of N. gonorrhoeae with Meningococcal B Vaccine: Matched Cohort Study (PMID:35642527)
• Effectiveness of MenB-4C Vaccine Against Gonorrhea: Systematic Review and Meta-analysis
• WHO Gonorrhoea fact sheet
• WHO: Gonorrhoea AMR results and vaccine development guidance, 2021
• Recent advances in understanding and combatting N. gonorrhoeae: genomic perspective (PMC8442004)
• High prevalence of tetracycline resistance in N. gonorrhoeae, 22 European countries, 2024
• Management of N. gonorrhoeae in the US: 2020/2021 CDC Treatment Guidelines Evidence Summary (PMID:35416971)
• Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020
• Multicenter Comparison of NAATs for Rectal and Oropharyngeal CT/NG
• Evaluation of Six Commercial NAATs for N. gonorrhoeae Detection
• NAAT for N. gonorrhoeae: An Ongoing Challenge
• Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria (PMID:21204865)
• CEACAM is not necessary for N. gonorrhoeae adherence/invasion (PMID:11580753)
• CEACAM binding determines outcome of N. gonorrhoeae infection along female reproductive tract
• Gonococcal outer membrane vesicle vaccines: bacterial population biology, clinical trials (npj Vaccines)
• Pre-clinical efficacy of candidate OMV gonococcal vaccine vs. 4CMenB (PMID:42259835)
• Breakthrough Rectal N. gonorrhoeae Infections After Meningococcal B Vaccination
• Resistance of mice to genital infection with N. gonorrhoeae (PMID:2506350)
• Estradiol-Treated Female Mice as Surrogate Hosts for N. gonorrhoeae Genital Tract Infections (PMID:21747807)
• N. gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development (PMID:28886683)
• Auranofin antibacterial activity in female mouse genital tract infection model
• N. gonorrhoeae co-infection exacerbates vaginal HIV shedding in humanized mice
• Sexually transmitted infections and increased risk of HIV co-infection (PMID:15653780)
• Risk of Subsequent HIV Infection Following STIs Among MSM